Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

ClinicalTrials.gov ID: NCT03916185

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03916185. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.

Study identification

NCT ID
NCT03916185
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
67 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Months to 25 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2019 (Actual)
Primary completion
Jan 22, 2024 (Actual)
Completion
Apr 25, 2024 (Actual)
Last update posted
Feb 21, 2025

2019 – 2024

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
David Geffen School of Medicine at UCLA NICHD CRS Los Angeles California 90095-1752 —
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program San Diego California 92103 —
Univ. of Colorado Denver NICHD CRS Aurora Colorado 80045 —
Emory University School of Medicine NICHD CRS Atlanta Georgia 30322 —
Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago Illinois 60612 —
Lurie Children's Hospital of Chicago (LCH) CRS Chicago Illinois 60614-3393 —
University of Maryland School of Medicine Center for Vaccine Development CRS Baltimore Maryland 21201 —
The Children's Mercy Hospital CRS Kansas City Missouri 64108-4619 —
Center for Vaccine Development CRS St Louis Missouri 63104 —
SUNY Stony Brook NICHD CRS Stony Brook New York 11794 —
Jacobi Med. Ctr. Bronx NICHD CRS The Bronx New York 10461 —
Duke Vaccine and Trials Unit CRS Durham North Carolina 27703 —
Gamble Center for Clinical Studies CRS Cincinnati Ohio 45229 —
Baylor College of Medicine/ Texas Children's Hospital NICHD CRS Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03916185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2025 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.